Full-Time
Software Engineer – New Grad
Confirmed live in the last 24 hours
Genesis Therapeutics
51-200 employees
AI-driven drug discovery for pharmaceuticals
Entry
Burlingame, CA, USA
Hybrid position in Burlingame, CA.
- A deep thinker who reasons from first principles, balances attention to detail with architectural thinking, and has an investigational curiosity to find the root cause of a problem
- Comfortable working across all levels of the software stack, from front-end interfaces to backend features to managing infrastructure
- Have experience writing production code and driving internship and school projects to completion
- Interested in learning more about drug discovery and machine learning
- Build and expand on tools for visualizing molecules and proteins, analyzing machine learning models, and managing complex chemical workflows
- Work closely with machine learning engineers and medicinal chemists to develop and productionize new computational methods for molecular property prediction
- Help scale our data infrastructure to handle billions of datapoints and thousands of parallel deep learning and molecular dynamics jobs
Genesis Therapeutics focuses on developing new medicines by using artificial intelligence in the drug discovery process. The company employs a method that combines 3D spatial graph modeling and advanced molecular simulation to identify potential drug candidates. This approach enables them to explore new chemical spaces and discover novel protein targets, which can lead to important new medicines. Unlike many competitors, Genesis Therapeutics operates on a business-to-business model, primarily partnering with other biotech and pharmaceutical companies, such as Eli Lilly, to provide their AI-driven drug discovery services. Their goal is to accelerate the development of new drugs through strategic partnerships and successful collaborations, while also generating revenue from upfront payments and potential future earnings based on the success of the drugs they help discover.
Company Stage
Series B
Total Funding
$272.5M
Headquarters
Burlingame, California
Founded
2019
6 month growth
↑ 21%1 year growth
↑ 49%2 year growth
↑ 132%
Simplify's Take
What believers are saying
- Recognition as a 'Fierce 15' company and one of America's most promising AI companies highlights Genesis Therapeutics' industry leadership and innovation.
- The $200M Series B funding will enable the company to advance its AI-enabled pipeline into clinical development, potentially leading to groundbreaking new treatments.
- Partnerships with industry giants like NVIDIA and Eli Lilly provide substantial opportunities for growth and collaboration.
What critics are saying
- The highly competitive biotech and AI-driven drug discovery sectors may pose challenges in maintaining a unique market position.
- Dependence on strategic partnerships and funding rounds could impact financial stability if future deals or investments do not materialize.
What makes Genesis Therapeutics unique
- Genesis Therapeutics leverages a unique combination of 3D spatial graph modeling and advanced molecular simulation, setting it apart from traditional drug discovery methods.
- Their AI platform, GEMS, is capable of generating novel drug-like molecules and making rapid, accurate predictions for challenging targets, which is a significant competitive advantage.
- Strategic partnerships with major pharmaceutical companies like Eli Lilly and significant funding rounds, including a $200M Series B, underscore their strong market position.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Competitive salary
Equity
Medical, dental, & vision insurance
401(k) program